Pediatric hepatocellular carcinoma: challenges and solutions
Open Access
- 1 January 2017
- journal article
- review article
- Published by Informa UK Limited in Journal of Hepatocellular Carcinoma
- Vol. ume 4, 15-21
- https://doi.org/10.2147/JHC.S94008
Abstract
Pediatric hepatocellular carcinoma: challenges and solutions Irene Schmid,1 Dietrich von Schweinitz,2 1Department of Pediatric Hematology and Oncology, 2Department of Pediatric Surgery, Dr. von Hauner Children`s Hospital, Ludwig-Maximilians-University, Munich, Germany Hepatocellular carcinoma (HCC) is a very rare entity in children, making it nearly impossible to orchestrate Phase II/III studies even as multinational cooperative trials. In contrast to adults, nearly 50% of the children have a response (α-fetoprotein decline and/or tumor shrinkage) to chemotherapeutic agents such as cisplatin and doxorubicin (PLADO), demonstrating that HCC in childhood can be chemotherapy sensitive. As a result, the main treatment options in pediatric HCC focus on systemic drug therapies and resection as the central therapy. In nonmetastatic patients with complete resection upfront, the 5-year event-free survival and overall survival has reached 80%–90%. In almost all reported studies, children received adjuvant chemotherapy (mostly PLADO), but it has never been proven that postoperative chemotherapy is superior to observation. No data are available for the effects of sorafenib. The 3-year survival is <20% in children with unresectable HCC independent of the chemotherapy given preoperatively. Currently, PLADO in combination with sorafenib is recommended with the goal of achieving operability status. Alternatively, data are promising for the combination of sorafenib with gemcitabine and oxaliplatin. For children with nonresectable and nonmetastastic liver tumors, it has been shown that the Milan criteria regarding liver transplantation are not applicable – individual decisions have to be made. Transarterial chemoembolization could be offered to patients with chemotherapy-resistant liver tumors for palliative care or potentially to achieve surgical resectability, and therefore cure. Information about the feasibility or effects of new agents or approaches as discussed in adult HCC patients is not available for childhood HCC. Research has to be done for characterizing the molecular and genomic mechanisms of pediatric HCC to support the development of novel therapeutic approaches and the implementation of personalized medicine. Keywords: hepatocellular carcinoma, pediatric, sorafenib, cisplatin, doxorubicinKeywords
This publication has 47 references indexed in Scilit:
- New agents on the horizon in hepatocellular carcinomaTherapeutic Advances in Medical Oncology, 2012
- Combining immunotherapy and targeted therapies in cancer treatmentNature Reviews Cancer, 2012
- Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular CarcinomaJournal of Clinical Oncology, 2011
- Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular CarcinomaJournal of Clinical Oncology, 2008
- The anticancer immune response: indispensable for therapeutic success?JCI Insight, 2008
- Preliminary experience with arterial chemoembolization for hepatoblastoma and hepatocellular carcinoma in childrenPediatric Blood & Cancer, 2005
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and AngiogenesisCancer Research, 2004
- Adult type vs. Childhood hepatocellular carcinoma—are they the same or different lesions? biology, natural history, prognosis, and treatmentMedical and Pediatric Oncology, 2002
- Genetic alterations in hepatoblastoma and hepatocellular carcinoma: Common and distinctive aspectsMedical and Pediatric Oncology, 2002
- Primary malignant tumor of liver in infants and children in TaiwanJournal of Pediatric Surgery, 1988